ArticleAdvances in therapy2025
Epidemiology and Steroid Dependency Reduction in Crohn's Disease During the Biologics Era: A Nationwide Population-Based Study.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evolution of surgical trends in Crohn's disease during the biologic era: population-based cohort insights from Taiwan, a low-endemicity region.Intestinal research · 2026Article
- Long-Term Outcomes and Therapeutic Strategies for Newly Diagnosed Crohn's Disease in the Biologic Era: A Nationwide Claims-Based Study from Japan.JMA journal · 2026Article
- Real-World Patterns of Immunomodulator Use in Patients with Inflammatory Bowel Disease Receiving Biologic Therapy Under a 54-Week Reimbursement Cap: A 12-Year Retrospective Single-Center Cohort from Taiwan.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCrohn's disease (CD), a subtype of inflammatory bowel disease, is a growing health concern. In this study, we examined the influence of biologics on prescription trends and steroid dependency.
methodsThis retrospective longitudinal analysis of insurance coverage spanned at least 1 year before and 1 year after the inflammatory bowel disease diagnosis and enrolled 4476 patients with CD. The study period was divided into the pre-biologics and post-biologics eras according to the date when the first CD-related prescription was issued. We examined prescription patterns, steroid dependency rates, and concurrent use of immunomodulators or biologics.
resultsThe CD incidence ranged from 1.6 to 1.3 cases per 100,000 patients between 2006 and 2018. During the pre-biologics era, the initial medications primarily comprised steroids (76.2%), followed by 5-aminosalicylic acid (44%) and immunomodulators (5.8%). During the post-biologics era, the initial prescription rates of steroids (69.8%) and 5-aminosalicylic acid (60.5%) remained high, and the Immunomodulators prescription rate increased to 14.7%. Steroid dependency was observed in 25.5 of 1000 and 22.1 of 1000 person-years during the pre-biologics and post-biologics eras, respectively. In the pre-biologics era, 6.1% of patients with steroid dependence received concurrent treatment with immunomodulators within the first 6 months. In the post-biologics era, this percentage increased to 24.2%, with some patients receiving immunomodulators or biologics.
conclusionsThe incidence rate in Taiwan showed a stable trend annually. Biologics approval and policy implementation resulted in increased immunomodulator use and decreased steroid dependency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.